Notably, HER2 CAR-T cells displayed heightened efficacy against HER2-positive colorectal cancer in patient-derived tumor xenograft (PDX) models, showcasing potent immunotherapeutic potential for mCRC in metastatic xenograft mouse models. Here, ERBB2 is linked to colorectal cancer.